Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor
暂无分享,去创建一个
Jeffrey P Leal | Hao Wang | Scott M Schuetze | Laurence H Baker | Lawrence H Schwartz | Richard L Wahl | L. Schwartz | R. Wahl | J. Leal | V. Bolejack | D. Reinke | S. Schuetze | L. Helman | L. Baker | Hao Wang | Brandon S. Luber | Joo Hyun O | Lee J Helman | Vanessa Bolejack | Brandon S Luber | Denise Reinke | Joo Hyun O
[1] D. Yee. Insulin-like growth factor receptor inhibitors: baby or the bathwater? , 2012, Journal of the National Cancer Institute.
[2] D. Reinke,et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Boellaard,et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[5] J. Eary,et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy , 2005, Cancer.
[6] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[7] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[8] D. Yee,et al. Disrupting insulin-like growth factor signaling as a potential cancer therapy , 2007, Molecular Cancer Therapeutics.
[9] R. Kurzrock,et al. Phase 1 clinical trials for sarcomas: the cutting edge , 2011, Current opinion in oncology.
[10] J. Eary,et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography , 2002, Cancer.
[11] Paul E Kinahan,et al. Variability in PET quantitation within a multicenter consortium. , 2010, Medical physics.
[12] T. Lumley,et al. Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.
[13] John O. Prior,et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Niels Møller,et al. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. , 2009, Endocrine reviews.
[15] L. Helman,et al. Targeting the insulin growth factor receptor 1. , 2012, Hematology/oncology clinics of North America.
[16] Adrian V. Lee,et al. Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition , 2010, Clinical Cancer Research.
[17] J. Eary,et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Min,et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[19] S L Zeger,et al. Multivariate Continuation Ratio Models: Connections and Caveats , 2000, Biometrics.